HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.

Abstract
The efficacy of ME1036, a novel parenteral carbapenem, was compared with that of vancomycin by using a rabbit model of methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. Compared with vancomycin, ME1036 reduced the bacterial counts in the vegetations at a lower dosage or over a shorter period of administration when it was used for the treatment of MRSA endocarditis.
AuthorsJun Nagura, Koji Kijima, Mizuyo Kurazono, Sho Takahata, Toshie Sugano, Yukari Tanaka, Yoko Hirai, Keiko Yamada, Yoshihiro Takayama, Eiki Shitara, Minoru Yonezawa
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 49 Issue 8 Pg. 3526-8 (Aug 2005) ISSN: 0066-4804 [Print] United States
PMID16048975 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Carbapenems
  • ME1036
  • Vancomycin
Topics
  • Animals
  • Anti-Bacterial Agents (pharmacokinetics, therapeutic use)
  • Carbapenems (pharmacokinetics, therapeutic use)
  • Colony Count, Microbial
  • Disease Models, Animal
  • Endocarditis, Bacterial (drug therapy, microbiology)
  • Female
  • Humans
  • Methicillin Resistance
  • Microbial Sensitivity Tests
  • Rabbits
  • Staphylococcal Infections (drug therapy, microbiology)
  • Staphylococcus aureus (drug effects, isolation & purification)
  • Treatment Outcome
  • Vancomycin (pharmacokinetics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: